PP_1170x120_10-25-21

Paxlovid (nirmatrelvir and ritonavir)

Hy-Vee Pharmacy now offering test-to-treat COVID-19 services

Hy-Vee Pharmacy now offering test-to-treat COVID-19 services

WEST DES MOINES, Iowa —Hy-Vee, Inc. announced this week that all Hy-Vee Pharmacy locations across its eight-state region now offer test-to-treat COVID-19 services using the COVID-19 antiviral, Paxlovid, to help treat mild-to-moderate cases of COVID-19 in certain patients who are at high risk for progression to severe COVID-19. Earlier this month, the FDA authorized state-licensed

FDA authorizes pharmacists to prescribe Paxlovid with certain limitations

FDA authorizes pharmacists to prescribe Paxlovid with certain limitations

WASHINGTON — The U.S. Food and Drug Administration on Wednesday revised the Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir and ritonavir), to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid. “The FDA recognizes the important role pharmacists have played and continue to play

Adheris Health